10/4/2012

Data from two clinical trials showed the SGLT-2 inhibitor empagliflozin, developed by Eli Lilly and Co. and Boehringer Ingelheim, helped lower blood pressure when used alone or in addition to metformin in adult type 2 diabetes patients.

Full Story:
Reuters

Related Summaries